{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T08:27:46Z","timestamp":1648628866854},"reference-count":32,"publisher":"FapUNIFESP (SciELO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Sao Paulo Med. J."],"abstract":"<jats:p> CONTEXT AND OBJECTIVES:  Glycoprotein inhibitors (abciximab, eptifibatide and tirofiban) are used in patients with unstable angina and non-ST-segment elevation myocardial infarction before percutaneous coronary intervention. Of these, tirofiban is the least effective. We hypothesized that the response to tirofiban might be associated with glycoprotein gene mutations.  DESIGN AND SETTING:  Prospective study at Emergency Unit, Heart Institute (InCor), University of S\u00e3o Paulo.  METHOD:  Intrahospital evolution and platelet aggregation in response to tirofiban were analyzed in relation to four glycoprotein mutations in 50 patients indicated for percutaneous coronary intervention: 17 (34%) with unstable angina and 33 (66%) with non-ST-segment elevation myocardial infarction. Platelet aggregation was analyzed using the Born method. Blood samples were obtained before and one hour after tirofiban infusion. Glycoproteins Ia (807C\/T ), Ib (Thr\/Met) , IIb (Ile\/Ser ) and IIIa (PIA ) were the mutations selected.  RESULTS:  Hypertension, dyslipidemia, diabetes, smoking, previous coronary artery disease and stroke were similar between the groups. Mutant glycoprotein IIIa genotypes had lower platelet aggregation before tirofiban administration than that of the wild genotype (41.0% \u00b1 22.1% versus 55.9% \u00b1 20.8%; P = 0.035). Mutant glycoprotein IIIa genotypes correlated moderately with lower platelet inhibition (r = -0.31; P = 0.030). After tirofiban administration, platelet glycoprotein Ia, Ib, IIb and IIIa mutations did not influence the degree of inhibition of platelet aggregation or intrahospital mortality.  CONCLUSIONS:  Mutations of glycoproteins Ia, Ib, IIb and IIIa did not influence platelet aggregation in response to tirofiban in patients with unstable angina and non-ST-segment elevation myocardial infarction.<\/jats:p>","DOI":"10.1590\/1516-3180.2015.00650808","type":"journal-article","created":{"date-parts":[[2016,1,17]],"date-time":"2016-01-17T04:59:13Z","timestamp":1453006753000},"page":"199-204","source":"Crossref","is-referenced-by-count":0,"title":["Gene mutations of platelet glycoproteins and response to tirofiban in acute coronary syndrome"],"prefix":"10.1590","volume":"134","author":[{"given":"Antonio de Padua","family":"Mansur","sequence":"first","affiliation":[{"name":"Universidade de S\u00e3o Paulo,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Roggerio","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00falio Yoshio","family":"Takada","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e9rola Michelle Vasconcelos","family":"Carib\u00e9","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solange Desir\u00e9e","family":"Avakian","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9lia Maria Cassaro","family":"Strunz","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","published-online":{"date-parts":[[2016,1,19]]},"reference":[{"issue":"23","key":"ref1","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJM199506083322306","article-title":"Platelet glycoprotein IIb\/IIIa receptors in cardiovascular medicine","volume":"332","author":"Lefkovits J","year":"1995","journal-title":"N Engl J Med"},{"issue":"4","key":"ref2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1053\/hj.1999.v138.a100459","article-title":"Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitors","volume":"138","author":"Kleiman NS","year":"1999","journal-title":"Am Heart J"},{"issue":"21","key":"ref3","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1056\/NEJM199805213382102","article-title":"Inhibition of the platelet glycoprotein IIb\/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators","volume":"338","year":"1998","journal-title":"N Engl J Med"},{"issue":"15","key":"ref4","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1161\/01.CIR.100.15.1609","article-title":"Intracoronary thrombus and platelet glycoprotein IIb\/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms). PRISM-PLUS Investigators","volume":"100","author":"Zhao XQ","year":"1999","journal-title":"Circulation"},{"issue":"25","key":"ref5","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJM200106213442502","article-title":"Comparison of two platelet glycoprotein IIb\/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization","volume":"344","author":"Topol EJ","year":"2001","journal-title":"N Engl J Med"},{"issue":"12","key":"ref6","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1161\/01.CIR.0000029744.01096.1F","article-title":"Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide","volume":"106","author":"Batchelor WB","year":"2002","journal-title":"Circulation"},{"issue":"5","key":"ref7","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/S0735-1097(00)00919-0","article-title":"Evidence of platelet activation during treatment with a GPIIb\/IIIa antagonist in patients presenting with acute coronary syndromes","volume":"36","author":"Cox D","year":"2000","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"ref8","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1161\/01.CIR.0000019581.22812.B2","article-title":"Platelet glycoprotein IIb\/IIIa inhibitors: recognition of a two-edged sword?","volume":"106","author":"Quinn MJ","year":"2002","journal-title":"Circulation"},{"issue":"11","key":"ref9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047304","article-title":"Modeling and molecular dynamics of HPA-1a and -1b polymorphisms: effects on the structure of the \u03b23 subunit of the \u03b1IIb \u03b23 integrin","volume":"7","author":"Jallu V","year":"2012","journal-title":"PLoS One"},{"issue":"4","key":"ref10","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1046\/j.1365-2141.2000.02300.x","article-title":"Defective platelet response to arachidonic acid and thromboxane A(2) in subjects with Pl(A2) polymorphism of beta(3) subunit (glycoprotein IIIa)","volume":"110","author":"Andrioli G","year":"2000","journal-title":"Br J Haematol"},{"issue":"12","key":"ref11","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.amjcard.2004.03.005","article-title":"Effect of glycoprotein IIIa PlA2 polymorphism on outcome of patients with stable coronary artery disease and effect of smoking","volume":"93","author":"Lopes NH","year":"2004","journal-title":"Am J Cardiol"},{"issue":"14","key":"ref12","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1161\/01.CIR.0000037106.76139.53","article-title":"ACC\/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina)","volume":"106","author":"Braunwald E","year":"2002","journal-title":"Circulation"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1113\/jphysiol.1963.sp007185","article-title":"The aggregation of blood platelets","volume":"168","author":"Born GV","year":"1963","journal-title":"J Physiol"},{"issue":"3","key":"ref14","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/nar\/16.3.1215","article-title":"A simple salting out procedure for extracting DNA from human nucleated cells","volume":"16","author":"Miller SA","year":"1988","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"ref15","first-page":"449","article-title":"Analysis of platelet glycoprotein Ia (alpha2 integrin) allele frequencies in three North American populations reveals genetic association between nucleotide 807C\/T and amino acid 505 Glu\/Lys (HPA-5) dimorphisms","volume":"80","author":"Reiner AP","year":"1998","journal-title":"Thromb Haemost"},{"issue":"1","key":"ref16","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2141.1995.tb08925.x","article-title":"Genomic RFLP typing of human platelet alloantigens Zw(PIA), Ko, Bak and Br (HPA-1, 2, 3, 5)","volume":"89","author":"Unkelbach K","year":"1995","journal-title":"Br J Haematol"},{"issue":"3","key":"ref17","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1161\/01.STR.29.3.581","article-title":"Platelet glycoprotein receptor IIIa polymorphism P1A2 and ischemic stroke risk: the Stroke Prevention in Young Women Study","volume":"29","author":"Wagner KR","year":"1998","journal-title":"Stroke"},{"issue":"9111","key":"ref18","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(05)79320-X","article-title":"PlA2 polymorphism and efficacy of aspirin","volume":"351","author":"Cook GE","year":"1998","journal-title":"Lancet"},{"issue":"4","key":"ref19","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1046\/j.1365-2141.2000.02267.x","article-title":"Relationship between bleeding time, aspirin and the PlA1\/A2 polymorphism of platelet glycoprotein IIIa","volume":"110","author":"Szczeklik A","year":"2000","journal-title":"Br J Haematol"},{"issue":"8","key":"ref20","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.amjcard.2005.06.039","article-title":"Variability in platelet aggregation following sustained aspirin and clopidogrel treatment in patients with coronary heart disease and influence of the 807 C\/T polymorphism of the glycoprotein Ia gene","volume":"96","author":"Angiolillo DJ","year":"2005","journal-title":"Am J Cardiol"},{"issue":"2","key":"ref21","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/01.STR.0000151362.65339.f9","article-title":"Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure?","volume":"36","author":"Gonzalez-Conejero R","year":"2005","journal-title":"Stroke"},{"issue":"7","key":"ref22","article-title":"The PlA1\/A2 polymorphism of glycoprotein IIIa as a risk factor for stroke: a systematic review and meta-analysis","volume":"9","author":"Floyd CN","year":"2014","journal-title":"PLoS One"},{"issue":"7","key":"ref23","article-title":"The PlA1\/A2 polymorphism of glycoprotein IIIa as a risk factor for myocardial infarction: a meta-analysis","volume":"9","author":"Floyd CN","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"ref24","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0002-9149(99)00321-5","article-title":"Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention","volume":"84","author":"Kereiakes DJ","year":"1999","journal-title":"Am J Cardiol"},{"issue":"12","key":"ref25","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1182\/blood.V98.12.3256","article-title":"Genetic variation in glycoprotein IIb\/IIIa (GPIIb\/IIIa) as a determinant of the responses to an oral GPIIb\/IIIa antagonist in patients with unstable coronary syndromes","volume":"98","author":"O'Connor FF","year":"2001","journal-title":"Blood"},{"issue":"1","key":"ref26","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1067\/mhj.2002.119763","article-title":"Reduced inhibition by abciximab in platelets with the PlA2 polymorphism","volume":"143","author":"Wheeler GL","year":"2002","journal-title":"Am Heart J"},{"issue":"7","key":"ref27","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/00008571-200210000-00011","article-title":"No evidence for an influence of the human platelet antigen-1 polymorphism on the antiplatelet effects of glycoprotein IIb\/IIIa inhibitors","volume":"12","author":"Weber AA","year":"2002","journal-title":"Pharmacogenetics"},{"issue":"4","key":"ref28","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/MBC.0b013e32835d546e","article-title":"PlA(1)\/PlA(2) polymorphism does not influence response to Gp IIb-IIIa inhibitors in patients undergoing coronary angioplasty","volume":"24","author":"Verdoia M","year":"2013","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"2","key":"ref29","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/MBC.0b013e328364b025","article-title":"Relationships of glycoproteins IIb-IIIa and Ib content with mean platelet volume and their genetic polymorphisms","volume":"25","author":"Khaspekova SG","year":"2014","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"12","key":"ref30","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/S0002-9149(02)02892-8","article-title":"Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban","volume":"90","author":"Schneider DJ","year":"2002","journal-title":"Am J Cardiol"},{"issue":"5","key":"ref31","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.cjca.2011.03.017","article-title":"Tirofiban use with clopidogrel and aspirin decreases adverse cardiovascular events after percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials","volume":"27","author":"Sethi A","year":"2011","journal-title":"Can J Cardiol"},{"issue":"6","key":"ref32","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/0002-8703(82)90169-7","article-title":"Hemorrheologic changes following acute myocardial infarction","volume":"104","author":"Dormandy J","year":"1982","journal-title":"Am Heart J"}],"container-title":["Sao Paulo Medical Journal"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/spmj\/v134n3\/1516-3180-spmj-_2015_00650808.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,6]],"date-time":"2018-03-06T01:09:04Z","timestamp":1520298544000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1516-31802016000300199&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,19]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,6]]}},"alternative-id":["S1516-31802016000300199"],"URL":"https:\/\/doi.org\/10.1590\/1516-3180.2015.00650808","relation":{},"ISSN":["1806-9460","1516-3180"],"issn-type":[{"value":"1806-9460","type":"electronic"},{"value":"1516-3180","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1,19]]}}}